Related Experiment Video

Updated: Jul 14, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Malignant teratoid/rhabdoid tumour: long-term survival

Barbara J Fisher, Kristopher E B Dennis, Lee-Cyn Ang

    The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
    |June 30, 2007
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Jul 14, 2026

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    Related Concept Videos

    The Retinoblastoma Gene01:20

    The Retinoblastoma Gene

    Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
    The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...

    Articles linked to this work by shared authors, journal, and citation graph.

    A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.

    Nature genetics·2026

    Distinct TAF15 amyloid filament folds define multiple subtypes of FTLD-TAF15.

    bioRxiv : the preprint server for biology·2026

    Brain transcriptomics highlight abundant gene expression and splicing alterations in non-neuronal cells in aFTLD-U.

    Acta neuropathologica·2025

    A Morphological Study of HLA-DR-Immunopositive Cells in Multiple Sclerosis Lesions and Their Implications for Pathogenesis.

    Diagnostics (Basel, Switzerland)·2024

    MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study.

    The Lancet. Neurology·2024

    Loss of Ramified Microglia Precedes Axonal Spheroid Formation in Adult-Onset Leukoencephalopathy with Axonal Spheroids.

    Free neuropathology·2023

    Cerebral Microbleeds and Superficial Siderosis: Vascular Correlates and Cognition in a Memory Clinic.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026

    Symptom Trajectories and Postoperative Treatment Response After Surgical Repair of Spinal CSF Leaks.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026

    Challenges and Care Recommendations of Persons with Functional Neurological Disorder and Care Partners: A Qualitative Study.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026

    Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

    Blood·2026

    Utility of multiparametric flow cytometry in the diagnosis and staging of Classic Hodgkin lymphoma-Experience in real-world practice.

    Cytometry. Part B, Clinical cytometry·2026

    Genetic thrombophilia in cancer-associated thrombosis: the fly plowing with the ox or an old player's new role?

    Haematologica·2026

    Making remissions last: the promise of maintenance in primary central nervous system lymphoma.

    Haematologica·2026

    Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

    Haematologica·2026

    The many faces (and phenotypes) of BCR::ABL1-driven acute leukemia.

    Haematologica·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us